Trial
NCT03434353
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
F-star Therapeutics, Inc.
Condition
Chronic Hepatitis B
Intervention
Inarigivir Soproxil
Why stopped
Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-04